3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
3
Lymphoid
2
Head & Neck
2
CNS
2
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Melanoma
23
Skin Neoplasms
12
Carcinoma, Non-Small-Cell Lung
9
Neoplasm Metastasis
8
Carcinoma, Basal Cell
8
Carcinoma, Merkel Cell
7
Neoplasms
6
Urinary Bladder Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Head and Neck Neoplasms
5
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Ovarian Neoplasms
3
Cutaneous Squamous Cell Carcinoma
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Renal Cell
3
Uveal Melanoma
2
Sarcoma
2
Pancreatic Neoplasms
2
Kidney Neoplasms
2
Carcinoma, Hepatocellular
2
Uterine Neoplasms
1
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck
1
Recurrence
1
Prostatic Neoplasms
1
Interventions
Peripheral Blood Stem Cell Transplantation
23
fludarabine phosphate
20
Cyclophosphamide
18
Mycophenolic Acid
16
Whole-Body Irradiation
15
Cyclosporine
15
Busulfan
12
Tacrolimus
11
Methotrexate
10
Antilymphocyte Serum
9
Radiotherapy
8
Melphalan
8
Etoposide
8
pembrolizumab
7
Methylprednisolone
6
Filgrastim
6
Sirolimus
4
Prednisone
4
Nivolumab
4
sargramostim
3
Vincristine
3
Transplantation
3
Therapeutics
3
Polymerase Chain Reaction
3
Cord Blood Stem Cell Transplantation
3
Amplified Fragment Length Polymorphism Analysis
3
mogamulizumab
2
merphos
2
bempegaldesleukin
2
Voriconazole
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
cemiplimab
×
Dermatologic
×
Clear all
NCT06022029
2025-12-24
ON-5001
OncoNano Medicine, Inc.
Phase 1
Recruiting
168 enrolled